메뉴 건너뛰기




Volumn 7, Issue 42, 2016, Pages 69014-69023

Samarium-153-EDTMP (Quadramet®) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trial

Author keywords

Cancer immunotherapy; Prostate cancer; Quadramet ; Radionuclide; Therapeutic vaccine

Indexed keywords

LEXIDRONAM SAMARIUM SM 153; PROSTATE SPECIFIC ANTIGEN; RILIMOGENE GALVACIREPVEC; CANCER VACCINE; ORGANOMETALLIC COMPOUND; ORGANOPHOSPHORUS COMPOUND; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; SAMARIUM SM-153 LEXIDRONAM;

EID: 85011716095     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/ONCOTARGET.10883     Document Type: Article
Times cited : (38)

References (33)
  • 2
    • 33846703339 scopus 로고    scopus 로고
    • Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain
    • Sartor O, Reid RH, Bushnell DL, Quick DP, Ell PJ. Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain. Cancer. 2007; 109:637-643
    • (2007) Cancer , vol.109 , pp. 637-643
    • Sartor, O.1    Reid, R.H.2    Bushnell, D.L.3    Quick, D.P.4    Ell, P.J.5
  • 10
    • 52649182085 scopus 로고    scopus 로고
    • Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant
    • Lechleider RJ, Arlen PM, Tsang KY, Steinberg SM, Yokokawa J, Cereda V, Camphausen K, Schlom J, Dahut WL, Gulley JL. Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant. Clin Cancer Res. 2008; 14:5284-5291
    • (2008) Clin Cancer Res , vol.14 , pp. 5284-5291
    • Lechleider, R.J.1    Arlen, P.M.2    Tsang, K.Y.3    Steinberg, S.M.4    Yokokawa, J.5    Cereda, V.6    Camphausen, K.7    Schlom, J.8    Dahut, W.L.9    Gulley, J.L.10
  • 13
    • 84871566470 scopus 로고    scopus 로고
    • Therapeutic cancer vaccines in prostate cancer: the quest for intermediate markers of response
    • Kim JW, Bilusic M, Heery CJ, Madan RA. Therapeutic cancer vaccines in prostate cancer: the quest for intermediate markers of response. Cancers (Basel). 2012; 4:1229-1246
    • (2012) Cancers (Basel) , vol.4 , pp. 1229-1246
    • Kim, J.W.1    Bilusic, M.2    Heery, C.J.3    Madan, R.A.4
  • 14
    • 84863177228 scopus 로고    scopus 로고
    • Initial PSA oscillations precede prolonged stable disease in a patient treated with a therapeutic cancer vaccine
    • Kim JW, Madan RA, Gulley JL. Initial PSA oscillations precede prolonged stable disease in a patient treated with a therapeutic cancer vaccine. Clin Genitourin Cancer. 2012; 10:43-46
    • (2012) Clin Genitourin Cancer , vol.10 , pp. 43-46
    • Kim, J.W.1    Madan, R.A.2    Gulley, J.L.3
  • 16
    • 84874699753 scopus 로고    scopus 로고
    • Therapeutic vaccines: the ultimate personalized therapy?
    • Gulley JL. Therapeutic vaccines: the ultimate personalized therapy? Hum Vaccin Immunother. 2013; 9:219-221
    • (2013) Hum Vaccin Immunother , vol.9 , pp. 219-221
    • Gulley, J.L.1
  • 19
    • 77953701142 scopus 로고    scopus 로고
    • Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway
    • Zitvogel L, Kepp O, Senovilla L, Menger L, Chaput N, Kroemer G. Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway. Clin Cancer Res. 2010; 16:3100-3104
    • (2010) Clin Cancer Res , vol.16 , pp. 3100-3104
    • Zitvogel, L.1    Kepp, O.2    Senovilla, L.3    Menger, L.4    Chaput, N.5    Kroemer, G.6
  • 20
    • 84902579129 scopus 로고    scopus 로고
    • Radiationinduced survival responses promote immunogenic modulation to enhance immunotherapy in combinatorial regimens
    • Gameiro SR, Ardiani A, Kwilas A, Hodge JW. Radiationinduced survival responses promote immunogenic modulation to enhance immunotherapy in combinatorial regimens. Oncoimmunology. 2014; 3:e28643
    • (2014) Oncoimmunology , vol.3
    • Gameiro, S.R.1    Ardiani, A.2    Kwilas, A.3    Hodge, J.W.4
  • 21
    • 84896694475 scopus 로고    scopus 로고
    • Attacking malignant cells that survive therapy: Exploiting immunogenic modulation
    • Hodge JW, Kwilas A, Ardiani A, Gameiro SR. Attacking malignant cells that survive therapy: Exploiting immunogenic modulation. Oncoimmunology. 2013; 2:e26937
    • (2013) Oncoimmunology , vol.2
    • Hodge, J.W.1    Kwilas, A.2    Ardiani, A.3    Gameiro, S.R.4
  • 22
    • 84901641673 scopus 로고    scopus 로고
    • Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
    • Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, Krainer M, Houede N, Santos R, Mahammedi H, Ng S, Maio M, Franke FA, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2014; 15:700-712
    • (2014) Lancet Oncol , vol.15 , pp. 700-712
    • Kwon, E.D.1    Drake, C.G.2    Scher, H.I.3    Fizazi, K.4    Bossi, A.5    van den Eertwegh, A.J.6    Krainer, M.7    Houede, N.8    Santos, R.9    Mahammedi, H.10    Ng, S.11    Maio, M.12    Franke, F.A.13
  • 24
    • 84899753178 scopus 로고    scopus 로고
    • PD-L1 is a novel direct target of HIF-1alpha, and its blockade under hypoxia enhanced MDSC-mediated T cell activation
    • Noman MZ, Desantis G, Janji B, Hasmim M, Karray S, Dessen P, Bronte V, Chouaib S. PD-L1 is a novel direct target of HIF-1alpha, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med. 2014; 211:781-790
    • (2014) J Exp Med , vol.211 , pp. 781-790
    • Noman, M.Z.1    Desantis, G.2    Janji, B.3    Hasmim, M.4    Karray, S.5    Dessen, P.6    Bronte, V.7    Chouaib, S.8
  • 26
    • 0036784603 scopus 로고    scopus 로고
    • Differential sensitivity of naive and memory CD8+ T cells to apoptosis in vivo
    • Grayson JM, Harrington LE, Lanier JG, Wherry EJ, Ahmed R. Differential sensitivity of naive and memory CD8+ T cells to apoptosis in vivo. J Immunol. 2002; 169:3760-3770
    • (2002) J Immunol , vol.169 , pp. 3760-3770
    • Grayson, J.M.1    Harrington, L.E.2    Lanier, J.G.3    Wherry, E.J.4    Ahmed, R.5
  • 27
    • 84908594586 scopus 로고    scopus 로고
    • Efficacy and safety of radium-223 dichloride in patients with castrationresistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial
    • Hoskin P, Sartor O, O'Sullivan JM, Johannessen DC, Helle SI, Logue J, Bottomley D, Nilsson S, Vogelzang NJ, Fang F, Wahba M, Aksnes AK, Parker C. Efficacy and safety of radium-223 dichloride in patients with castrationresistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol. 2014; 15:1397-1406
    • (2014) Lancet Oncol , vol.15 , pp. 1397-1406
    • Hoskin, P.1    Sartor, O.2    O'Sullivan, J.M.3    Johannessen, D.C.4    Helle, S.I.5    Logue, J.6    Bottomley, D.7    Nilsson, S.8    Vogelzang, N.J.9    Fang, F.10    Wahba, M.11    Aksnes, A.K.12    Parker, C.13
  • 28
    • 0025075142 scopus 로고
    • Leuprolide therapy for prostate cancer An association with scintigraphic "flare" on bone scan
    • Johns WD, Garnick MB, Kaplan WD. Leuprolide therapy for prostate cancer. An association with scintigraphic "flare" on bone scan. Clin Nucl Med. 1990; 15:485-487
    • (1990) Clin Nucl Med , vol.15 , pp. 485-487
    • Johns, W.D.1    Garnick, M.B.2    Kaplan, W.D.3
  • 31
    • 0036157424 scopus 로고    scopus 로고
    • Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen
    • Terasawa H, Tsang KY, Gulley J, Arlen P, Schlom J. Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen. Clin Cancer Res. 2002; 8:41-53
    • (2002) Clin Cancer Res , vol.8 , pp. 41-53
    • Terasawa, H.1    Tsang, K.Y.2    Gulley, J.3    Arlen, P.4    Schlom, J.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.